Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866209 | 1.00 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1439006 | 1.00 | LMNA (0.42) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL2430897 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL1406056 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL376390 | 0.89 | CA1 (0.46) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL3053679 | 0.89 | LMNA (0.44) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL1563474 | 0.88 | HTT (0.43) | LMNAALDH1A1EPHX2EPHX1CA1 | |
| SCHEMBL12404075 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL12404070 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 | |
| SCHEMBL14440773 | 0.85 | EPHX2 (0.49) | LMNAALDH1A1EPHX2SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| EP-3969446-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4219466-A1 | COMPUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220204478-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-114245794-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3969446-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2020231977-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-3380468-B1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2020-05-20 | — | — | EP | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7795256-B2 | Thieno-pyridinone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2007-04-05 | — | — | US | disclosed |
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | LMNA 4363/4885ALDH1A1 2574/4885EPHX2 3658/4885 |
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | LMNA 3015/4885ALDH1A1 331/4885EPHX2 1943/4885 |
| US-20220204478-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | LMNA 1632/4885ALDH1A1 1485/4885EPHX2 1691/4885 |
| US-20060247269-A1 | Thienopyridone derivatives as kinase inhibitors | MAPKAPK2, MAP3K6, MAP3K12 | LMNA 4433/4885ALDH1A1 2307/4885EPHX2 3060/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | LMNA 2568/4885ALDH1A1 1179/4885EPHX2 3856/4885 |
| US-20070078131-A1 | Thieno-pyridinone derivatives as kinase inhibitors | MAP3K6, MAP4K2, MAP3K15 | LMNA 2907/4885ALDH1A1 2586/4885EPHX2 1883/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2522/4885ALDH1A1 3319/4885EPHX2 2094/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | LMNA 3852/4885ALDH1A1 2651/4885EPHX2 3620/4885 |
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | LMNA 3529/4885ALDH1A1 807/4885EPHX2 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.